Navigation Links
JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM)

CHARLESTON, S.C., Feb. 27 /PRNewswire/ -- JSJ Pharmaceuticals is pleased to announce the introduction of its new aesthetic division, Vitivia(TM). Vitivia(TM) will focus on medically based aesthetics and utilize the clinical roots of JSJ Pharmaceuticals in the development of science-based, result-oriented products.

Vitivia(TM)'s first product introduction will be its Pro:Vitamin line. Topical vitamins have long been recognized as important tools in the anti-aging process. The benefits of most topical vitamins, however, have been limited by the inability to stabilize vitamins when exposed to air and light. For products that have attempted to address this stability issue, long lists of preservative agents have been the answer. Vitivia(TM)'s Pro:Vitamin has found an innovative solution to these challenges.

In light of the fact that today's consumers desire natural ingredients, free of chemical preservatives, fragrances, coloring, or other allergens, Vitivia(TM)'s Pro:Vitamin line combines pure concentrations of natural ingredients with the best of modern science. This formulation is then placed in individual biodegradable unit dose packaging insuring each application of Pro:Vitamin has never been exposed to light or air. As a result, the concentration of the first application is as pure and stable as the last.

"With the continued growth of medically based aesthetics, Vitivia(TM) will be an important growth factor for the future of JSJ Pharmaceuticals," stated JSJ's Chief Operating Officer, Jonathan Alba. "The introduction of the clinically proven Pro:Vitamin line will be a key part of the long-term foundation of the Vitivia(TM) division of JSJ," stated Alba.

Vitivia(TM)'s Pro:Vitamin line is available through physician offices nationally. For more information regarding the purchase or distribution of Vitivia(TM) products visit or call 1-888-975-4848.

About JSJ:

JSJ Pharmaceuticals, based in Charleston, SC, is a growing specialty pharmaceutical company focused on the development and commercialization of prescriptive products to meet the diverse needs of patients suffering from a wide range of dermatological conditions. More information can be found about JSJ Pharmaceuticals at

Media Contact:

Jon Knowles

843.965.8333 ext. 104

This release was issued through eReleases(TM). For more information, visit

SOURCE JSJ Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
2. NPS Pharmaceuticals Announces Senior Management Changes
3. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
4. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
7. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
8. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):